New Streamlined PBS Authorisation of cetuximab

Due to advocacy by the MOGA Oncology Drugs Working Group, in November 2023, the approved Product Information for cetuximab was updated to include a weekly and every two weeks dosing regimen for metastatic colorectal cancer (mCRC) indications.

Whilst the PBS Streamline Authority codes remain unchanged, the new maximum quantity across all mCRC PBS indications is now 1100 mg, allowing for both weekly and every two weeks dosing of cetuximab. 

To access the PBS Schedule for cetuximab CLICK HERE 

To refer to the PBS for full authority information on all mCRC treatment options, visit: www.pbs.gov.au